Close Menu

NEW YORK (GenomeWeb) — Fulgent Genetics reported after the close of the market on Tuesday that its third quarter revenues rose 25 percent year over year amid a strong increase in billable tests delivered.

For the three-month period ended Sept. 30, the Temple City, California-based company posted revenues of $5.6 million compared with $4.5 million a year earlier. The number of billable tests delivered in the quarter climbed 37 percent to 5,569, Fulgent said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.